Search for GHK-Cu and cognition and you will find confident claims that this peptide protects the ageing brain. There is real research behind those claims. It is also a much stranger and more limited body of work than the summaries suggest, and understanding what each piece actually is changes what you can conclude from it.
This article covers GHK-Cu as a cosmetic ingredient. It is not medical advice, and nothing here has been evaluated by the FDA.
Key Takeaways
- The frequently cited 2017 paper is a gene-expression analysis, not an experiment. It used the Broad Institute Connectivity Map to describe genes GHK modulates that relate to nervous system function and cognitive decline [1].
- Its three authors were affiliated with Skin Biology, a company that sells copper peptide products. That does not make the analysis wrong, but it is a disclosure that belongs in any honest summary.
- The first behavioural animal test appeared in 2026 as a preprint: aged mice given GHK-Cu intranasally for eight weeks improved spatial learning in both sexes; a five-day intraperitoneal course improved males transiently only [2].
- The two routes produced opposite molecular signatures in the hippocampus, intranasal suppressing oxidative phosphorylation and MYC pathways, intraperitoneal activating them [2]. The mechanism is not settled.
- Both delivery routes were injection or nasal. Nothing here involves skin, and none of it is human evidence.
The Paper Everybody Cites Is Not a Study of Brains
The 2017 Brain Sciences paper is the source of most of what circulates about GHK and neurodegeneration [1]. It is worth being precise about what it contains.
It is a review and gene-expression analysis. The authors describe GHK as a copper-binding peptide that declines with age and has documented effects across many tissues, then present the genes GHK modulates that are relevant to nervous system health, drawn from Connectivity Map data. The Connectivity Map is a database of gene expression signatures produced by compounds in cell lines; querying it tells you which transcriptional patterns a molecule resembles or reverses. It is a hypothesis-generating tool.
No mice were treated. No people were treated. No neurons were exposed to the peptide and then measured for survival or function in that paper. The finding is that GHK’s transcriptional signature touches genes involved in nervous system function, which is a reason to run an experiment rather than a result of one.
The authors were all affiliated with Skin Biology, a copper peptide company, and the corresponding author is the researcher who originally isolated GHK and has spent decades advocating for it. That history is genuinely relevant to the field [3] and is also a commercial interest that a reader deserves to be told about.
The 2026 Mouse Study Is the Real Experiment
In 2026 a group at the University of Washington posted a behavioural test [2]. It is a preprint on Research Square, meaning it has been made public before completing peer review, so its conclusions could change.
It was not the first, and the earlier one is the stronger citation. In 2025 a peer-reviewed study gave 5xFAD transgenic mice 15 mg/kg intranasal GHK-Cu three times a week for three months, from four months of age to seven, and reported delayed cognitive impairment alongside reduced amyloid plaques and lower MCP1-mediated inflammation in the frontal cortex [5]. That paper also notes in passing that GHK-Cu had already been shown to improve cognitive performance in aging mice, so the behavioural literature predates both studies [5].
The distinction worth holding onto is what each one is for. The 5xFAD work is a disease model, asking whether GHK-Cu changes Alzheimer’s-like pathology in animals engineered to develop it. The preprint is a normal-aging model, asking whether it changes age-related decline in ordinary old mice. Neither is a human study, and the 5xFAD result is the one that has survived review.
The design: C57BL/6J mice aged 20 to 21 months received GHK-Cu at 15 mg/kg, either by intraperitoneal injection for five days or intranasally for eight weeks. Hippocampal-dependent learning was measured with a spatial navigation task, and the hippocampus was then examined by immunohistochemistry and bulk RNA sequencing.
Intranasal treatment improved escape latency across trials two to four in both males and females. Intraperitoneal dosing produced a transient improvement in males on trial two only, with nothing sustained and no effect in females. Intranasal treatment raised synaptophysin in females and lowered GFAP in both sexes, GFAP being a marker of reactive astrocytes and a standard readout of neuroinflammation. The intraperitoneal course lowered TGF-beta, GFAP and MCP-1 in males and reduced p21, a senescence marker, in females.
The Two Routes Disagreed at the Molecular Level
The most interesting and least quotable part of the preprint is that the transcriptomics went in opposite directions depending on route [2]. Intranasal GHK-Cu produced coordinated suppression of oxidative phosphorylation and MYC target pathways, with attenuated PI3K-AKT-mTOR signalling in females. Intraperitoneal dosing activated oxidative phosphorylation, DNA repair and MYC targets.
Both routes improved learning to some degree, by molecular programmes that look like opposites. The authors read this as evidence that functional improvement can arise from divergent biological states and that route and exposure duration are themselves determinants of the response.
That is an honest reading, and it is also a warning against any tidy story about how GHK-Cu helps the brain. A mechanism that flips sign depending on whether you inject or inhale is not yet a mechanism.
Why None of This Reaches a Serum
The two routes tested were injection into the peritoneal cavity and delivery into the nose. Intranasal administration is used in neuroscience specifically because it partly bypasses the blood-brain barrier along olfactory and trigeminal pathways. It is a deliberate technique for getting molecules to the brain that otherwise cannot get there.
Topical application is the opposite situation. Getting GHK-Cu through the stratum corneum into the dermis at all is the unresolved problem of the topical literature [4]. Systemic circulation from a face serum, then crossing into the brain, is not something the delivery data supports.
The dose is the other gap: 15 mg/kg in a mouse, given daily. That is a pharmacological dose by a parenteral route, not a cosmetic exposure.
The Accurate Summary
GHK declines with age, and its transcriptional signature overlaps genes relevant to nervous system function. That observation has been in the literature since 2017 and comes from an analysis rather than an experiment, produced by people with a commercial stake in the peptide.
In 2026 someone finally ran the experiment, in old mice, by routes chosen to reach the brain, and got a behavioural improvement with a molecular picture that does not yet cohere. It has not been peer reviewed.
That is an early, interesting research thread. It is not a reason to use a skincare product for cognition, and it is not a reason to take a peptide.
Frequently Asked Questions
Can a GHK-Cu serum affect your brain?
There is no evidence for that and no plausible route. The animal work that produced behavioural improvement used injection into the abdomen or delivery into the nose, at 15 mg/kg [2]. A serum on the face is not a route to the hippocampus.
Is the 2017 brain paper an experiment?
No. It is a gene-expression analysis using the Broad Institute Connectivity Map, describing genes GHK modulates that are relevant to nervous system function [1]. No animals or people were treated in it, and its authors were at a company that sells copper peptides.
Has GHK-Cu been tested for cognition in animals?
Yes, in mice. A peer-reviewed 2025 study found intranasal GHK-Cu delayed cognitive impairment and reduced amyloid plaques in a transgenic Alzheimer’s model [5]. A separate 2026 preprint found aged mice given GHK-Cu intranasally for eight weeks improved on a spatial navigation task in both sexes, while a five-day intraperitoneal course produced only a transient improvement in males [2]; that one has not completed peer review.
Should anyone take GHK-Cu for memory?
No. Preprint mouse data with a route no consumer product uses is not a basis for taking anything, and self-administering peptides carries risks this site covers separately.
References
- Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences (2017). PMID 28212278
- Mazzola J, Rosenfeld M, Tucker M, et al. Middle-Aged Mice Treated With GHK-Cu Peptide Administered Intraperitoneally or Intranasally Show Behavioral Rescue but Divergent Hippocampal Aging Programs. Research Square (preprint, not peer reviewed) (2026). PMID 42245779
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences (2018). PMID 29986520
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically Applied GHK as an Anti-Wrinkle Peptide: Advantages, Problems and Prospective. BioImpacts (2025). PMID 39963574
- Tucker M, et al. Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. Aging pathobiology and therapeutics (2025). PMID 40766919
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical or dermatological advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
